Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Therapeutics Scores $45 Million To Develop Novel Virology Treatments

This article was originally published in The Pink Sheet Daily

Executive Summary

United Therapeutics Corp. gets a $45 million tranched grant from the U.S. National Institute of Allergy and Infectious Disease to develop broad-spectrum compounds against influenza and Dengue.

You may also be interested in...



Visterra Strikes Deal With Pfizer, Presents Strong Data For Flu Drug

The start-up supplied few details about its arrangement with its Big Pharma partner, but receives cash as it prepares to take a promising influenza therapy into the clinic.

Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA

The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.

Vaccine Upstart Inviragen Aims to Capture Dengue Market

Six-year-old Inviragen may be the biotech of the future.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel